HETERO LABS LIMITED
PharmaHETERO LABS LIMITED is a pharmaceutical company focused on Oncology.
HETERO LABS LIMITED's Key Drugs
HETERO LABS LIMITED's core commercial portfolio centers on AZILSARTAN MEDOXOMIL, spanning Oncology — its most strategically important drugs approved in the last 15 years.
HETERO LABS LIMITED's Recent FDA Approvals
New NDA/BLA approvals for HETERO LABS LIMITED over the last two years — novel drugs only, excluding generics and label supplements.
HETERO LABS LIMITED's Therapeutic Areas
HETERO LABS LIMITED's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HETERO LABS LIMITED's Top Competitors
HETERO LABS LIMITED's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HETERO LABS LIMITED Pipeline Snapshot
Active clinical trials for HETERO LABS LIMITED across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AZILSARTAN MEDOXOMIL leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling